Clinical outcomes of capecitabine-based versus S-1-based regimens as first-line chemotherapy in patients with unresectable or metastatic gastric cancer: a propensity score matched single-center comparison
Clinical outcomes of capecitabine-based versus S-1-based regimens as first-line chemotherapy in patients with unresectable or metastatic gastric cancer: a propensity score matched single-center comparison
复制标题
基于卡培他滨与基于 S-1 的方案作为不可切除或转移性胃癌患者一线化疗的临床结果：倾向评分匹配的单中心比较
DOI：
10.21037/jgo-20-52
复制
发表时间：
2020-08-01
影响因子：
2.1
通讯作者：
Liu, Yunpeng
中科院分区：
文献类型：
--
作者：
Wang, Jin;Li, Zhi;Liu, Yunpeng
Background: Fluoropyrimidine-based regimens are the cornerstone of first-line chemotherapy for metastatic gastric cancer (GC). Capecitabine or S-1 might be used as an alternative to infusional 5-fluorouracil, especially in pan-Asian. This study aimed to compare the clinical outcomes of capecitabine-based and S-1-based regimens as first-line chemotherapy in Chinese patients with unresectable or metastatic GC.Methods: We conducted a retrospective study including unresectable or metastatic GC patients treated with the capecitabine-based or S-1-based regimen as first-line chemotherapy at the First Hospital of China Medical University. Propensity score matching (PSM) analysis was performed to reduce selection bias. Overall survival (OS) outcomes were compared using the Kaplan-Meier method and log-rank test. Prognostic significance was determined using multivariate Cox regression analysis. In addition, subgroup analyses were conducted to determine the effectiveness of capecitabine-based and S-1-based regimens in clinically relevant patient subsets.Results: The clinical data of 469 patients included between October 2005 and September 2018. PSM. analysis identified 187 patients receiving capecitabine-based or S-1-based regimen. No significant difference in OS (10.7 vs. 11.1 months, P=0.523) was detected between the two groups after PSM.. In the subgroup analysis, the median OS (12.2 vs. 9.3 months, P=0.013) was longer for patients with peritoneum metastasis who received the capecitabine-based regimen compared to those who received the S-I -based regimen.Conclusions: No significant difference in clinical outcomes was observed between the capecitabine and S-1-based regimen as first-line chemotherapy for metastatic or unresectable GC patients in China. The capecitabine-based regimen should be considered in the treatment of the GC patients with peritoneum metastasis.
